Sionna Therapeutics (NASDAQ:SION) Trading Up 5.3% – Time to Buy?

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) traded up 5.3% during trading on Friday . The company traded as high as $48.05 and last traded at $47.67. 303,922 shares traded hands during trading, a decline of 19% from the average session volume of 375,250 shares. The stock had previously closed at $45.29.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SION shares. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus lifted their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. JonesTrading increased their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Citizens Jmp restated a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Sionna Therapeutics Stock Performance

The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -25.60 and a beta of 1.33. The business has a fifty day simple moving average of $40.74 and a 200 day simple moving average of $39.63.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, sell-side analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. The trade was a 6.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This represents a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 989,630 shares of company stock worth $44,987,483. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG grew its holdings in shares of Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after purchasing an additional 433 shares in the last quarter. Bank of America Corp DE increased its position in shares of Sionna Therapeutics by 8.8% in the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares during the period. MetLife Investment Management LLC raised its stake in Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after purchasing an additional 532 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the fourth quarter worth about $36,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.